scholarly journals Etiology and management of hypertension in patients with cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Turab Mohammed ◽  
Meghana Singh ◽  
John G. Tiu ◽  
Agnes S. Kim
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Kinase Inhibitors ◽  
Alkylating Agents ◽  
Immunosuppressive Agents ◽  
Proteasome Inhibitors ◽  
Pressure Control ◽  
Vegf Inhibitors ◽  
Patients With Cancer ◽  
Established Risk Factor

AbstractThe pathophysiology of hypertension and cancer are intertwined. Hypertension has been associated with an increased likelihood of developing certain cancers and with higher cancer-related mortality. Moreover, various anticancer therapies have been reported to cause new elevated blood pressure or worsening of previously well-controlled hypertension. Hypertension is a well-established risk factor for the development of cardiovascular disease, which is rapidly emerging as one of the leading causes of death and disability in patients with cancer. In this review, we discuss the relationship between hypertension and cancer and the role that hypertension plays in exacerbating the risk for anthracycline- and trastuzumab-induced cardiomyopathy. We then review the common cancer therapies that have been associated with the development of hypertension, including VEGF inhibitors, small molecule tyrosine kinase inhibitors, proteasome inhibitors, alkylating agents, glucocorticoids, and immunosuppressive agents. When available, we present strategies for blood pressure management for each drug class. Finally, we discuss blood pressure goals for patients with cancer and strategies for assessment and management. It is of utmost importance to maintain optimal blood pressure control in the oncologic patient to reduce the risk of chemotherapy-induced cardiotoxicity and to decrease the risk of long-term cardiovascular disease.

Abstract 086: Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial

2017 ◽  
Vol 10 (suppl_3) ◽  
Author(s):  
Neha J Pagidipati ◽  
Ann Marie Navar ◽  
Karen S Pieper ◽  
Jennifer B Green ◽  
M. A Bethel ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Latin America ◽  
North America ◽  
Secondary Prevention ◽  
Eastern Europe ◽  
Statin Therapy ◽  
Smoking Status ◽  
Pressure Control ◽  
Patients With Diabetes

Background: Intensive risk factor modification significantly improves outcomes for patients with diabetes and cardiovascular disease (CVD). However, the degree to which secondary prevention treatment targets are achieved in international clinical practice is unknown. Methods: Attainment of 5 secondary prevention targets—aspirin use, lipid control (low-density lipoprotein cholesterol (LDL-C) <70 mg/dL or statin therapy), blood pressure control (<140 mmHg systolic, <90 mmHg diastolic), angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and non-smoking status—was evaluated among 14,671 patients from 38 countries with diabetes and known CVD at entry into TECOS. Logistic regression was used to evaluate the association between individual and regional factors and target achievement. Results: Overall, 29.9% of patients with diabetes and CVD had all 5 secondary prevention measures at target. North America had the highest proportion (41.2%), whereas Western Europe, Eastern Europe, and Latin America had proportions of approximately 25%. The likelihood of having individual prevention components at target also varied by region: compared with North America, individuals in all other regions were less likely to have blood pressure at goal, and individuals in Eastern Europe and Latin America were less likely to have LDL-C at target or to be on statin therapy (see Figure). Overall, blood pressure control (57.9%) had the lowest overall attainment while non-smoking status had the highest (89%). Conclusions: On a global scale, significant opportunities exist to improve the quality of cardiovascular secondary prevention care among patients with diabetes and CVD, which in turn could lead to reduced risk of downstream cardiovascular events.

scholarly journals EFFECTS OF INTENSIVE BLOOD PRESSURE CONTROL IN PATIENTS WITH EVIDENT CARDIOVASCULAR DISEASE

2018 ◽  
Vol 71 (11) ◽  
pp. A1914
Author(s):  
Dimitrios Terentes-Printzios ◽  
Charalambos Vlachopoulos ◽  
Konstantinos Aznaourids ◽  
Nikolaos Ioakeimidis ◽  
Panagiotis Xaplanteris ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Intensive Blood Pressure

Kidney Transplant

2013 ◽  
Author(s):  
Ian Smith
Keyword(s):  
Quality Of Life ◽  
Blood Pressure ◽  
Renal Transplantation ◽  
End Stage Renal Disease ◽  
Pediatric Patients ◽  
Immunosuppressive Agents ◽  
Pressure Control ◽  
Stage Renal Disease ◽  
End Stage

Renal transplantation is the preferred treatment for pediatric patients who have end-stage renal disease. A successful transplant improves intellectual and behavioral development, quality of life, and survival, with the survival at 10 years being as high as 83% (Kim et al., 1991). We can optimize the chance of success by understanding the pathophysiology involved and applying this knowledge to guide our management of perioperative fluid balance, electrolyte anomalies, anemia, blood pressure control, and comorbidities. Also critical is an appreciation of the effects and consequences of the various immunosuppressive agents that are used. Close communication is required between the pediatrician, surgeon, and anesthesiologist.

scholarly journals Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years

JAMA ◽  
2016 ◽  
Vol 315 (24) ◽  
pp. 2673 ◽  
Author(s):  
Jeff D. Williamson ◽  
Mark A. Supiano ◽  
William B. Applegate ◽  
Dan R. Berlowitz ◽  
Ruth C. Campbell ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Disease Outcomes
Sign in / Sign up

Export Citation Format

Share Document